TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31798953
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (hand osteoarthritis education, assistive devices, CMCJ orthoses, and exercises)
Study: 29974634
Drug: Aspirin as
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin as an adjunct to compression therapy
Study: 21322823
Drug: Rivastigmine therapy
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine therapy
Study: 12182952
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of glucose
Study: 12182952
Drug: Intraduodenal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal infusion of fat
Study: 10359029
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF), 1000 mg/m2/d
Study: 10359029
Drug: Azathioprine (AZA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (AZA), 2 mg/kg on the first post-operative day
Study: 8557012
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of rocuronium (9.9 +/- 1.3 micrograms kg-1 min-1)
Study: 8557012
Drug: Surgical patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical patients receiving comparable infusions
Study: 29738405
Drug: Group aerobic
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group aerobic and strength training (twice weekly for 24 weeks, 60 minutes each session using ankle weights, latex resistance bands, and dumbbells)
Study: 26813471
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of valsartan (group B)
Study: 26813471
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of valsartan combined with tacrolimus (group C)
Study: 26813471
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of valsartan (group A)
Study: 20352259
Drug: Laparoscopic cholecystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic cholecystectomy + irrigation of gallbladder bed with 20 mL 0.5% bupivacaine solution
Study: 20352259
Drug: Laparoscopic cholecystectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic cholecystectomy + irrigation of gallbladder bed with bupivacaine + 10 mL 0.5% bupivacaine solution every 6 h
Study: 17606880
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide 500 mg once daily for 4 days combined with oral prednisone 60 mg once daily for 5 days (n = 16)
Study: 17606880
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide and prednisone (treatment group)
Study: 10458232
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with ifosfamide/etoposide on days 1-3 and cyclophosphamide/doxorubicin on day 5, followed by granulocyte colony-stimulating factor; maintenance included four alternating cycles of ifosfamide/etoposide and doxorubicin/CTX.
Study: 10458232
Drug: CTX dose
Normalized name: CTx-PDE6b
DrugBank: CTx-PDE6b (DB17858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX dose levels during maintenance (two arms).
Study: 10458232
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimen including dose-intensification.
Study: 7563558
Drug: 22-mg transdermal
Normalized name: methylphenidate 2.22 MG/HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-mg transdermal nicotine therapy with minimal counseling
Study: 7563558
Drug: 44-mg transdermal
Normalized name: moxidectin 1.44 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44-mg transdermal nicotine therapy with minimal counseling
Study: 7563558
Drug: 22-mg transdermal
Normalized name: methylphenidate 2.22 MG/HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-mg transdermal nicotine therapy with individual counseling
Study: 7563558
Drug: 44-mg transdermal
Normalized name: moxidectin 1.44 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44-mg transdermal nicotine therapy with individual counseling
Study: 7563558
Drug: 22-mg transdermal
Normalized name: methylphenidate 2.22 MG/HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-mg transdermal nicotine therapy with group counseling
Study: 7563558
Drug: 44-mg transdermal
Normalized name: moxidectin 1.44 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44-mg transdermal nicotine therapy with group counseling
Study: 7563558
Drug: Minimal contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal contact treatment
Study: 7563558
Drug: 44-mg transdermal
Normalized name: moxidectin 1.44 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 44-mg transdermal nicotine therapy
Study: 7563558
Drug: 22-mg transdermal
Normalized name: methylphenidate 2.22 MG/HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22-mg transdermal nicotine therapy
Study: 115801
Drug: Intranasal self‐administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal self‐administration of an aqueous solution of a glutaraldehyde‐treated timothy grass pollen allergen
Study: 30540715
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (IV TXA) 2g (1g before incision and 1g before wound closure)
Study: 30540715
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (PO TXA) 1.95g 2 hours preoperatively
Study: 27236888
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule (XFC), 0.5 g each pill, three pills each time, 3 times per day for 3 months
Study: 27236888
Drug: Sulfasalazine (SASP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (SASP), 0.25 g per tablet, 4 tablets each time, twice per day for 3 months
Study: 25256187
Drug: BDD-NET (therapist-supported,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDD-NET (therapist-supported, Internet-based cognitive-behavioral therapy) for 12 weeks
Study: 22493419
Drug: Trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (4 mg loading dose followed by 2 mg weekly)
Study: 22493419
Drug: Lapatinib (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib (1,500 mg orally daily)
Study: 22493419
Drug: Trastuzumab and
Normalized name: pertuzumab and trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab and lapatinib (1,000 mg orally daily)
Study: 22493419
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (control group not explicitly defined)
Study: 20138357
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery (APCam01)
Study: 20138357
Drug: Closed-loop insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop insulin delivery (APCam03)
Study: 17179256
Drug: Landiolol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol at 0.1 mg/kg infused 4 min before intubation in normotensive patients
Study: 17179256
Drug: Landiolol at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol at 0.2 mg/kg in hypertensive patients
Study: 17179256
Drug: Fentanyl at
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl at 2 μg/kg
Study: 17179256
Drug: Landiolol (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (any dose)
Study: 12488239
Drug: buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (10 mg twice daily)
Study: 12488239
Drug: paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: paroxetine (20 mg daily)
Study: 12488239
Drug: venlafaxine-XR (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: venlafaxine-XR (75 mg daily)
Study: 9121851
Drug: 2-hourly CPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-hourly CPT
Study: 9121851
Drug: 4-hourly CPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-hourly CPT
Study: 1292072
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg capsule three times daily
Study: 1292072
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (multiple-vitamin tablet three times daily)
Study: 3966421
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg PN X HCl
Study: 3966421
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg PN X HCl
Study: 3966421
Drug: 10.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg PN X HCl
Study: 3966421
Drug: 20.0 mg
Normalized name: RUXOLITINIB 20.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20.0 mg PN X HCl
Study: 27926661
Drug: Low-dose prostacyclin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prostacyclin infusion (1.0 ng/kg/min)
Study: 24373022
Drug: Paramedian inserted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paramedian inserted mini-implants
Study: 24373022
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (median mini-implants of the same size)
Study: 15076779
Drug: Anesthesia (lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia (lidocaine injected into the anterior talofibular and calcaneofibular ligament, 1.5 cc each)
Study: 11818693
Drug: Interferon-alpha alone
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha alone or in combination with ribavirin
Study: 9803049
Drug: Prolonged transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged transdermal fentanyl (FENtd)
Study: 8087191
Drug: Aluminium-adsorbed pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminium-adsorbed pertussis vaccine
Study: 8087191
Drug: Non-adsorbed pertussis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adsorbed pertussis vaccine
Study: 8087191
Drug: Two-component vaccine
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-component vaccine as primary immunization
Study: 8087191
Drug: Monocomponent vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocomponent vaccine as primary immunization
Study: 27765695
Drug: 1,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 IU daily
Study: 27765695
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU weekly
Study: 17543413
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone once daily for 6 months
Study: 15146932
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide 5‐mononitrate (5‐ISMN) tablet
Study: 15146932
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide 5‐mononitrate intravenous infusion
Study: 15146932
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide dinitrate (ISDN) intravenous infusion
Study: 11219479
Drug: Fluvastatin ER
Normalized name: fluvastatin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin ER 80 mg QPM
Study: 11219479
Drug: Fluvastatin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin IR 40 mg QPM
Study: 11219479
Drug: Fluvastatin IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin IR 40 mg BID
Study: 2739019
Drug: Antilipid A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antilipid A antibody
Study: 474664
Drug: Animal supplements
Normalized name: animals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal supplements
Study: 474664
Drug: Vegetable supplements
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable supplements
Study: 28723837
Drug: Lidocaine 1.5%
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5% with epinephrine 5 μg/mL
Study: 15059069
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B lipid complex (ABLC) at 1 mg/kg/d
Study: 15059069
Drug: Conventional amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional amphotericin B (c‐AmB) at 0.6 mg/kg/d
Study: 2421751
Drug: xamoterol 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol 0.025 mg kg‐1
Study: 31211469
Drug: Typing pattern
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typing pattern monitored remotely during a 6-month follow-up while dopaminergic medications were being titrated.
Study: 31211469
Drug: Novel algorithm
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel algorithm based on recursive neural networks for detecting responses to medication.
Study: 31211469
Drug: Dopaminergic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopaminergic treatment titration.
Study: 30084893
Drug: Telephone-administered interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-administered interpersonal psychotherapy (tele-IPT)
Study: 24625273
Drug: Ultrasound-guided subacromial
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided subacromial corticosteroid injection and a physiotherapist-led exercise programme
Study: 24625273
Drug: Ultrasound-guided subacromial
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided subacromial corticosteroid injection and an advice and exercise leaflet
Study: 24625273
Drug: Blind subacromial
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind subacromial corticosteroid injection and a physiotherapist-led exercise programme
Study: 24625273
Drug: Blind subacromial
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind subacromial corticosteroid injection and an advice and exercise leaflet
Study: 24625273
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between injection interventions
Study: 15741836
Drug: Pizotifen (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen (1.5 mg)
Study: 10213009
Drug: irinotecan (CPT-11)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan (CPT-11) at a dose of 350 mg/m2 every 3 weeks
Study: 7537967
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight (LMW) heparin
Study: 2170885
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of radiation therapy
Study: 25785441
Drug: Rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (10 mg) + Zinc (30 mg/d) + Selenium (150 μg/d)
Study: 24015990
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (200 mg iron sucrose, three daily infusions starting within 24 hours of admission)
Study: 21412833
Drug: LEV 500
Normalized name: Cetylev 500 MG Effervescent Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 500 mg/day
Study: 21412833
Drug: LEV 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 1,000 mg/day
Study: 14749240
Drug: Flaxseed (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (25 g ground flaxseed muffin)
Study: 14749240
Drug: Soy (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy (25 g soy flour muffin)
Study: 11545629
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin (0.3% ophthalmic solution every 30 minutes for 4 hours before surgery)
Study: 11545629
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (0.3% ophthalmic solution every 30 minutes for 4 hours before surgery)
Study: 11545629
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical and oral ofloxacin (one 400-mg tablet administered 24-26, 12-14, and 2 hours before surgery)
Study: 11545629
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical and oral ciprofloxacin (four 100-mg tablets administered 24-26, 12-14, and 2 hours before surgery)
Study: 11545629
Drug: Combined topical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined topical and oral therapy with ofloxacin
Study: 11545629
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy alone (ofloxacin)
Study: 3122381
Drug: Mannitol 20%
Normalized name: mannitol 20% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 20% (250 ml) with moderate hydration (2.5 L)
Study: 23277304
Drug: Social learning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social learning and cognitive behavioral therapy
Study: 21450262
Drug: Imagining daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagining daily activities (DA) for 5 minutes per day over two weeks
Study: 18974717
Drug: Caffeine (CAF)
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine (CAF) 6 mg.kg(‐1) body mass
Study: 16816222
Drug: Oxcarbazepine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (mean dose=1515 mg/day)
Study: 12960189
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of glucose metabolism with duration of deafness in postlingually deaf patients
Study: 10596684
Drug: Bradykinin inhalation
Normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin inhalation
Study: 10596684
Drug: Inhaled L‐ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled L‐ASA (90 mg/mL, 4 mL)
Study: 8537687
Drug: Pneumococcal glycoprotein
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal glycoprotein conjugate vaccine (serotypes 6B, 14, 18C, 19F, and 23F linked to CRM197)
Study: 31725692
Drug: Preoperative acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative acetaminophen and carbohydrate drinks
Study: 22167079
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with Improvac (2 ml s. c.); administered at 12 weeks and 18 weeks
Study: 20020791
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic + intravenous ketorolac tromethamine
Study: 20020791
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac tromethamine alone
Study: 15068574
Drug: Tailored, nurse-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored, nurse-administered smoking cessation intervention with telephone counseling
Study: 7768259
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan (16 mg)
Study: 7768259
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan (up to 400 mg)
Study: 373358
Drug: Fenfluramine therapy
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine therapy
Study: 6404954
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg three times a day
Study: 29843899
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiation therapy (SBRT) 24 Gy
Study: 22476616
Drug: Glucosidase inhibitors
Normalized name: Alpha glucosidase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosidase inhibitors
Study: 18243498
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months goserelin followed by no additional therapy
Study: 7733122
Drug: Tolbutamide 250
Normalized name: tolbutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide 250 to 1,000 mg
Study: 1914055
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nalbuphine after lidocaine anaesthesia
Study: 1914055
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nalbuphine after lidocaine anaesthesia
Study: 1914055
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nalbuphine after lidocaine anaesthesia
Study: 1914055
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nalbuphine after 2-chloroprocaine anaesthesia
Study: 1914055
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nalbuphine after 2-chloroprocaine anaesthesia
Study: 1914055
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nalbuphine after 2-chloroprocaine anaesthesia
Study: 31283920
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT screening (LDCT) in patients with COPD